Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29099726 | 0.95 | KMT2A (0.38) | CD274MEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL29080873 | 0.90 | CD274 (0.31) | CD274 | |
| SCHEMBL16072020 | 0.83 | ALDH1A1 (0.41) | CD274MEN1KMT2ACYP2C19CYP4F2 | |
| SCHEMBL25187231 | 0.80 | CD274 (0.40) | CD274MEN1KMT2ACYP2C19CYP4F2 | |
| SCHEMBL31042946 | 0.80 | CD274 (0.40) | CD274MEN1KMT2ACYP2C19CYP4F2 | |
| SCHEMBL14726436 | 0.80 | CD274 (0.40) | CD274MEN1KMT2ACYP2C19CYP4F2 | |
| SCHEMBL25405744 | 0.80 | CD274 (0.40) | CD274MEN1KMT2ACYP2C19CYP4F2 | |
| SCHEMBL20237134 | 0.80 | CD274 (0.40) | CD274MEN1KMT2ACYP2C19CYP4F2 | |
| SCHEMBL14094871 | 0.80 | CD274 (0.40) | CD274MEN1KMT2ACYP2C19CYP4F2 | |
| SCHEMBL3743278 | 0.80 | CD274 (0.40) | CD274MEN1KMT2ACYP2C19CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-12448367-B2 | Phthalazine derivatives as pyruvate kinase modulators | SITRYX THERAPEUTICS LIMITED (GB) | 2025-10-21 | — | — | US | disclosed |
| EP-4612132-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-20250230143-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| CN-120166987-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2019035863-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034688-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035863-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183956-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018183964-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2017133667-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | CD274 4654/4885MEN1 4063/4885KMT2A 1148/4885 |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK1, PDK2, PDK4 | CD274 3099/4885MEN1 3836/4885KMT2A 603/4885 |
| US-20250230143-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK1, PDK2, PDK3 | CD274 2520/4885MEN1 3786/4885KMT2A 876/4885 |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HPGDS, IP6K1 | CD274 2776/4885MEN1 2746/4885KMT2A 1334/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | CD274 2828/4885MEN1 4869/4885KMT2A 4424/4885 |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | NEK1, NEK5, NEK11 | CD274 2378/4885MEN1 2744/4885KMT2A 2969/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CD274 4593/4885MEN1 142/4885KMT2A 4008/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CD274 4734/4885MEN1 1978/4885KMT2A 3362/4885 |
| US-12448367-B2 | Phthalazine derivatives as pyruvate kinase modulators | PDK1, PDK2, PDK3 | CD274 2520/4885MEN1 3786/4885KMT2A 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.